Tác dụng điều chỉnh rối loạn lipid máu của viên nang linh quế truật cam - nhị trần thang trên lâm sàng

Abstract

This study was carried out to evaluate the effect of LQTCT-NTT capsules on primary dyslipidemia in obesity grade I and II.

Objects and methods: 90 primary obese patients grade I and II (including pattern of internal harassment of dampness phlegm and spleen kidney yang deficiency syndrome) that were taken orally LQTCT-NTT 500mg, 08 capsules / day for 45 consecutive days.

Results and conclusions: LQTCT – NTT have the effect of adjusting primary dyslipidemia in obese people with grade I and II: markedly reduced TC 21,19% (p < 0,0001), TG 25,38% (p<0,05), LDL-C 16,36% (p < 0,005), Non HDL-C 28,80% ( p< 0,001) and considerably increased HDL-C 9,2%(p<0,001), Significantly decreased BMI 5% (p<0.05) when compared to pretreatment; Significantly improved the manifestations of internal harassment of dampness phlegm and spleen kidney yang deficiency according to the traditional medicine. The effect of LQTCT-NTT on spleen kidney yang deficiency syndrome was tended to be better than the internal harassment of dampness phlegm, but there was no difference (p> 0.05).